We will email you to start the conversation.
Albert Labs International Corp. (Albert Labs (CSE: ABRT) (FSE: VB50), the “Company”), a pharmaceutical drug development company focussed on gaining regulatory approval for active compounds to treat various mental health conditions, has announced the filing of a New International PCT Patent Application (No. PCT/CA2022/051281) with the United States Patent and Trademark Office (USPTO) for its proprietary manufacturing process.
This proprietary manufacturing methodology developed and validated in-house at Albert Labs’ Vancouver facility facilitates the production and scaling of highly potent yields of its KRN-101 Active Pharmaceutical Ingredient (API). The bioreactor technology is efficient, economical, and sustainable, ensuring pharmaceutical quality and consistent production of its natural, tryptamine-based medicines.
The Company is utilising this proprietary manufacturing technology to produce its primary drug target, the psilocybin-based KRN-101, which will treat cancer patients suffering from mental distress. It will also support the company’s growth plans as it pursues a clinical expansion strategy with various global regulatory authorities.
Dr Jean Saayman, Research and Development Lead for Albert Labs: “This technology is a very innovative approach to solving the scale-up issues faced by processes utilising high-value shear-sensitive organisms. The novel bioreactor and processing methods result in better yields with lower post-processing requirements, and the advantages for commercial API production are exciting. The R&D team worked diligently on this innovative technology, and we are all very proud of the benefits.”
Dr Michael Raymont, CEO of Albert Labs: “This milestone demonstrates the Company’s in-house biochemical engineering expertise and simultaneously establishes Albert Labs as a market leader in the controlled production and scaling of pharmaceutical quality, natural tryptamine-based medicines.
Quality and consistency are critically important conditions in order to meet regulatory requirements, and this presents a challenge to companies like Albert Labs, who are looking to utilise natural products to treat patients suffering from mental health challenges. To have the capability to produce natural medicines at scale and to pharmaceutical quality, provides the Company with an invaluable asset.
Traditional mental health treatments are unable to effectively and safely treat many mental health disorders. These disorders represent a currently unmet and urgent need. Utilising this technology for our primary drug target, KRN-101, Albert Labs is working to improve the lives of millions who are currently suffering.”
Albert Labs is a pharmaceutical drug development company, focussed on gaining regulatory approval for active compounds in the treatment of mental health, and providing rapid access to effective prescription medicines for people suffering from mental health disorders. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which the needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognised clinical route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines.
Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs’ first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.
The company’s goal is to deliver effective medicines to suffers with mental health concerns in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.
Albert Labs (CSE: ABRT) (FSE: VB50) is publicly listed on the Canadian Securities Exchange (CSE).
You can find more details about Albert Labs on our website here.
Albert Labs International Corp.
Dr. Michael Raymont
Chief Executive Officer & Chairman
For further information please contact:Email: firstname.lastname@example.orgWebsite: albertlabs.comCanada: +1 778-819-0740United Kingdom: +44 1625 324 960
This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.
The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.
© 2022 Albert Labs. All Rights Reserved
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact email@example.com